Sign in

    Larry Holub • Webcast Questions

    Larry Holub is a Director at MZ North America, specializing in investor relations and strategic communication with a focus on facilitating Q&A and webcast engagement for publicly traded companies. He has supported earnings calls and events for firms such as Monogram Technologies, Expion360, and Transcat, helping to shape and clarify investor messaging but does not serve as a financial analyst directly covering corporate fundamentals or issuing ratings. Holub joined MZ North America prior to 2021, having participated in high-visibility webcast events and virtual investor conferences. His professional background centers on corporate advisory for IR functions, and there is no publicly documented record of FINRA registration, securities analysis credentials, or quantifiable portfolio performance typically associated with traditional Wall Street analysts.

    Larry Holub's questions to Heartbeam Inc (BEAT) leadership

    Larry Holub's questions to Heartbeam Inc (BEAT) leadership • Q1 2025

    Question

    Webcast questions moderated by Larry Holub focused on the key takeaways from the VALID-ECG pivotal study for FDA clearance and the company's current manufacturing capabilities and exposure to tariffs.

    Answer

    CEO Robert Eno explained that the VALID-ECG study was pivotal because it successfully demonstrated the similarity of their patient-used synthesized ECG to the standard 12-lead ECG, which strengthens the case for FDA clearance and physician adoption. Executive Timothy Cruickshank added that manufacturing is U.S.-based, minimizing direct tariff exposure, with a current capacity of thousands of devices per month and a stable supply chain.

    Ask Fintool Equity Research AI